October Term 2022 · Docket 21-757

Does a patent claim covering all antibodies binding to a specific protein target require proof that every single one is easy to make?

Amgen argues its broad patent claim is valid because it provides a general roadmap. Sanofi argues the claim is invalid because it covers antibodies that are difficult to create.

Official caption
Amgen Inc. v. Sanofi
Latest argument session
Latest official Court activity
Latest verified event
Decided
Sources analyzed through
Post Opinion

Verified source milestones

  1. — An official oral-argument transcript was verified.
  2. — An official oral-argument transcript was verified.
  3. — An official Court opinion was verified.

The arguments, in order

This case may have been argued more than once. Each entry below uses that session's official transcript. Later arguments do not erase earlier ones.

  1. Argument 1 ·

    What happened at the argument

    Amgen's counsel stated that claiming a lot while enabling a little short-changes the public.

    Amgen's counsel argued that Sanofi failed to identify any antibody requiring undue experimentation.

    Sanofi's counsel noted that scientists do not use the patented method if an antibody already exists.

    Justice Sotomayor questioned why Amgen had not made a specific antibody if the process was easy.

    Read the official transcript for this argument · Official argument details

    Sources used for this argument breakdown

A citizen's guide to the whole case

What this case is about

The case centers on the scope of a patent claim. Amgen holds a patent for antibodies that bind to a specific spot on the PCSK9 protein. Sanofi argues this claim is too broad. Amgen argues the claim is valid because it teaches a general method to find such antibodies.

Official sources for this section

How the case got here

The Supreme Court heard oral argument in this case on March 27, 2023.

Official sources for this section

What each side wants

Amgen wants the court to uphold its broad patent claim as valid.

Sanofi wants the court to invalidate the patent claim as too broad.

Official sources for this section

What each side says

Amgen argues the patent provides a sufficient roadmap for making the claimed antibodies.

Sanofi argues the claim covers antibodies that require undue experimentation to create.

Official sources for this section

What the justices asked

Justice Thomas asked if the process only produces one specific antibody.

Justice Sotomayor asked what is unique about Amgen's process compared to finding antibodies generally.

Official sources for this section

Why it matters

This case defines the boundary between a valid patent claim and an overbroad one. It determines how much specific detail a patent must provide when claiming a large class of molecules. The outcome affects the balance between rewarding invention and keeping scientific knowledge accessible.

Official sources for this section

What happens next

This article currently covers the argument record. Use the official docket link for later case activity.

Official sources for this section

Official Court provenance

Official docket and case history · Official Supreme Court oral-argument detail page

Verified official opinions and orders

Title and summary sources

Revision history

  1. Revision 1 · Post Opinion ·

    Correction: Rewritten to the concise citizen-facing editorial standard.

  2. Revision 2 · Post Opinion ·

    Correction: Migrated to the dated official Court activity contract without model use.

Download this sanitized case as JSON